Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Forte Biosciences, Inc.NASDAQ: FBRX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $1.97M fell 42.6% year over year, behind the -28.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 30.5% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -19.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.97M-30.5% QoQ
Last fiscal yearDec 2025
$12.41M-19.3% YoY
LTMMar 2026
$10.95M-28.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.6%-100.0%-57.4 pp
1 year-19.3%-100.0%-80.7 pp
3-year CAGR+14.3%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
12.41M USD
Year-over-year change
-19.3%
4-year CAGR
+12.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.8% is the 9th highest of 10, against a peer median of -3.8%.
  • Over three fiscal years its annual growth of +14.3% compares with a peer median of +2.6%.
FBRX Competitors
Selling, General & Admin for FBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$47.37M USD-20.9%-4.0%257.2%
FATEFate Therapeutics, Inc.LTM Mar 2026$42.34M USD-49.3%-18.0%670.4%
NKTXNkarta, Inc.LTM Mar 2026$25.06M USD-19.7%+4.0%—
PEPGPepGen Inc.LTM Mar 2026$22.56M USD+1.9%+16.6%—
MOLNMolecular Partners AGLTM Mar 2026CHF 16.11M CHF-3.8%-12.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$15.52M USD-5.5%-6.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$13.7M USD+20.3%+31.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$13.02M USD+27.1%+2.6%2479.6%
ACTUActuate Therapeutics IncLTM Mar 2026$12.2M USD+39.9%+47.3%—
FBRXForte Biosciences, Inc.LTM Mar 2026$10.95M USD-28.8%+14.3%—
Peer median (excluding FBRX) —-3.8%+2.6%670.4%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue36K09K39K64K
Gross Profit(36K)0(9K)(39K)(64K)
Gross Margin—————
Research & Development13.85M5.59M21.86M21.19M58.25M
Selling, General & Admin7.63M8.3M10.62M15.37M12.41M
Operating Expenses21.49M13.9M32.48M36.56M70.66M
Depreciation & Amortization36K36K9K39K64K
EBITDA(21.67M)(13.84M)(31.47M)(35.44M)(68.27M)
EBITDA Margin—————
Operating Income(21.49M)(13.9M)(32.49M)(36.6M)(70.66M)
Operating Margin—————
Interest Income001.12M1.31M2.72M
Interest Expense00000
Other Income / Expenses(222K)17K1.01M1.12M2.32M
Income Before Tax(21.71M)(13.88M)(31.48M)(35.48M)(68.34M)
Pre-Tax Margin—————
Income Tax Expense00001.04M
Net Income(21.71M)(13.86M)(31.48M)(35.48M)(69.38M)
Net Margin—————
EPS (Basic)(38.85)(19.96)(24.92)(12.17)(4.71)
EPS (Diluted)(38.85)(19.96)(24.92)(12.17)(4.71)
Weighted Avg Shares558.71K695.34K1.26M2.92M147.18M
Weighted Avg Shares (Diluted)558.71K695.34K1.26M2.92M147.18M

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.